Literature DB >> 33207208

JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.

Kathryn D Tuttle1, Katherine A Waugh1, Paula Araya1, Ross Minter1, David J Orlicky2, Michael Ludwig1, Zdenek Andrysik3, Matthew A Burchill4, Beth A J Tamburini5, Colin Sempeck1, Keith Smith1, Ross Granrath1, Dayna Tracy1, Jessica Baxter1, Joaquin M Espinosa6, Kelly D Sullivan7.   

Abstract

Individuals with Down syndrome (DS; trisomy 21) display hyperactivation of interferon (IFN) signaling and chronic inflammation, which could potentially be explained by the extra copy of four IFN receptor (IFNR) genes encoded on chromosome 21. However, the clinical effects of IFN hyperactivity in DS remain undefined. Here, we report that a commonly used mouse model of DS overexpresses IFNR genes and shows hypersensitivity to IFN ligands in diverse immune cell types. When treated repeatedly with a TLR3 agonist to induce chronic inflammation, these animals overexpress key IFN-stimulated genes, induce cytokine production, exhibit liver pathology, and undergo rapid weight loss. Importantly, the lethal immune hypersensitivity and cytokine production and the ensuing pathology are ameliorated by JAK1 inhibition. These results indicate that individuals with DS may experience harmful hyperinflammation upon IFN-inducing immune stimuli, as observed during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, pointing to JAK1 inhibition as a strategy to restore immune homeostasis in DS.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Down syndrome; JAK inhibitors; autoimmunity; autoinflammation; cytokine storm; immune system; immune therapy; interferon; liver disease; trisomy 21

Mesh:

Substances:

Year:  2020        PMID: 33207208      PMCID: PMC7727402          DOI: 10.1016/j.celrep.2020.108407

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  59 in total

Review 1.  Aicardi-Goutières syndrome and the type I interferonopathies.

Authors:  Yanick J Crow; Nicolas Manel
Journal:  Nat Rev Immunol       Date:  2015-06-05       Impact factor: 53.106

Review 2.  Therapeutic Perspectives for Interferons and Plasmacytoid Dendritic Cells in Rheumatoid Arthritis.

Authors:  Ramzi Nehmar; Alexandre Mariotte; Aurore de Cauwer; Jean Sibilia; Seiamak Bahram; Philippe Georgel
Journal:  Trends Mol Med       Date:  2018-03-05       Impact factor: 11.951

3.  Predominant role of innate pro-inflammatory cytokines in vitiligo disease.

Authors:  Nasser Gholijani; Mohammad-Reza Yazdani; Ladan Dastgheib
Journal:  Arch Dermatol Res       Date:  2019-10-16       Impact factor: 3.017

Review 4.  Mouse models of Down syndrome: gene content and consequences.

Authors:  Meenal Gupta; A Ranjitha Dhanasekaran; Katheleen J Gardiner
Journal:  Mamm Genome       Date:  2016-08-18       Impact factor: 2.957

5.  Fatty Infiltration of the Liver in Patients with Mongolism and in Children with Hydrocephaly and Microcephaly.

Authors:  E C Roosen-Runge
Journal:  Am J Pathol       Date:  1947-01       Impact factor: 4.307

6.  Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells.

Authors:  P Matthys; R Dijkmans; P Proost; J Van Damme; H Heremans; H Sobis; A Billiau
Journal:  Int J Cancer       Date:  1991-08-19       Impact factor: 7.396

7.  Down syndrome is associated with elevated risk of celiac disease: a nationwide case-control study.

Authors:  Karl Mårild; Olof Stephansson; Lena Grahnquist; Sven Cnattingius; Gabriella Söderman; Jonas F Ludvigsson
Journal:  J Pediatr       Date:  2013-02-08       Impact factor: 4.406

8.  Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease.

Authors:  Juliet M Taylor; Myles R Minter; Andrew G Newman; Moses Zhang; Paul A Adlard; Peter J Crack
Journal:  Neurobiol Aging       Date:  2013-10-29       Impact factor: 4.673

9.  Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities.

Authors:  Zhongyou Li; Tao Yu; Masae Morishima; Annie Pao; Jeffrey LaDuca; Jeffrey Conroy; Norma Nowak; Sei-Ichi Matsui; Isao Shiraishi; Y Eugene Yu
Journal:  Hum Mol Genet       Date:  2007-04-05       Impact factor: 6.150

10.  Signaling a link between interferon and the traits of Down syndrome.

Authors:  Gina Kirsammer; John D Crispino
Journal:  Elife       Date:  2016-09-06       Impact factor: 8.140

View more
  6 in total

Review 1.  Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches.

Authors:  Clíona Farrell; Paige Mumford; Frances K Wiseman
Journal:  Front Neurosci       Date:  2022-06-07       Impact factor: 5.152

Review 2.  Autoimmunity and Genetic Syndromes: A Focus on Down Syndrome.

Authors:  Marta Ferrari; Stefano Stagi
Journal:  Genes (Basel)       Date:  2021-02-13       Impact factor: 4.096

Review 3.  Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.

Authors:  Dingzhong Li; Jianbing Hu; Dian Li; Weijun Yang; Shuang-Feng Yin; Renhua Qiu
Journal:  Top Curr Chem (Cham)       Date:  2021-01-11

4.  Comprehensive analysis of pathways in Coronavirus 2019 (COVID-19) using an unsupervised machine learning method.

Authors:  Golnaz Taheri; Mahnaz Habibi
Journal:  Appl Soft Comput       Date:  2022-08-17       Impact factor: 8.263

Review 5.  Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.

Authors:  Tomer Illouz; Arya Biragyn; Maria Florencia Iulita; Lisi Flores-Aguilar; Mara Dierssen; Ilario De Toma; Stylianos E Antonarakis; Eugene Yu; Yann Herault; Marie-Claude Potier; Alexandra Botté; Randall Roper; Benjamin Sredni; Jacqueline London; William Mobley; Andre Strydom; Eitan Okun
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

Review 6.  Down syndrome and type I interferon: not so simple.

Authors:  Louise Malle; Dusan Bogunovic
Journal:  Curr Opin Immunol       Date:  2021-06-23       Impact factor: 7.268

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.